The goal of this study is to determine whether the SuperCAP intervention program is superior to control in reducing disability from baseline to the post-intervention assessment in people with Post-COVID-19 Condition. The main question it aims to answer is whether participants assigned to SuperCAP experience a greater reduction in disability, defined as an improvement of at least 5 points on the WHODAS 2.0 from baseline to the post-intervention visit, compared with participants in the control group.
Official registry: https://clinicaltrials.gov/study/NCT07530757 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · enrollment listed as 100
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are SuperCAP intervention program, or Psychoeducational intervention. The registry lists allocation as randomized. The goal of this study is to determine whether the SuperCAP intervention program is superior to control in reducing disability from baseline to the post-intervention assessment in people with Post-COVID-19 Condition.
They plan to enroll about 100 people at Badalona. Taking part typically means using or being fitted with a device plus check-ins.
Randomized Controlled Trial to Assess the Efficacy of a Supervised Computerized Active Program (SuperCAP) to Improve Cognition and Daily Functioning in People With Post-COVID-19 Condition
Interventions: SuperCAP intervention program, Psychoeducational intervention
Primary outcome (registry wording): To determine whether the SuperCAP intervention program is superior to control in reducing disability.
Anna Prats, PhD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data.
NCT04362150 · Official ClinicalTrials.gov record · University of California, San Francisco
We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks.
NCT05764538 · Official ClinicalTrials.gov record · Chang Gung Memorial Hospital
This study aims to verify the how well it works/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and myalgia, as well as sleep problems. Transcranial direct current stimulation is used in the field of Physiotherapy and Rehabilitation, with results that have proven to be effective for treating patients suffering from symptoms like migraines, headaches, chronic pain, fibromyalgia, or chronic neuropathic pain and insomnia.
NCT05780450 · Official ClinicalTrials.gov record · Fundación Universidad Católica de Valencia San Vicente Mártir
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary